News
-
-
-
-
-
PRESS RELEASE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Xenetic Biosciences, Inc. has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia to advance the development of its systemic DNase program, targeting neutrophil extracellular traps involved in cancer progression. The company believes that the data generated by its research and development collaborations are crucial for unlocking the potential of its DNase technology and driving a clinical path for its lead solid tumor indications. The agreement with UVA provides a significant addition to Xenetic's development capabilities and resources, accelerating development timelines. Dr. Allan Tsung, an internationally recognized surgical oncologist and scientist, will oversee the research conducted under the agreement. Xenetic is working towards its planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy. For more information, visit Xenetic Biosciences' website at www.xeneticbio.com. -
-
-
Buildout, Inc. Unveils Game-Changing Technology Stack including an AI-Enabled Mobile App
-
Heal and Find Hope After a Friendship Breakup in When Best Friends Aren't Forever by Kristen Reed, Out Now
-
Viking Capital Announces Closing of Latest 268 Acquisition in Atlanta
-
Aflac: 6 Common Myths About Supplemental Insurance
-
Gabriel Resources Ltd. Initial Closing of Private Placement
-
Dalata Hotel Group PLC: HOL-Holding(s) in Company*
-
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
-
M&G Credit Income Investment Trust plc: Net Asset Value(s)
-
Funding Circle Plc: POS-Transaction in Own Shares
-
Explore Copenhagen's Culinary Gem: Khun Juk Oriental, Winner of the 2023 Thai Select Signature Award and Esteemed Taittinger Ambassador
-
VOGO : French National Handball League chooses VOGO to referee the French men’s championship (“Liqui Moly Starligue”).
-
ENGIE Q1 2024 Financial Information
-
Covivio Hotels successfully priced a €500 million 9-year Green Bond
-
Covivio Hotels successfully priced a €500 million 9-year Green Bond
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2024